1 active not recruiting, 1 not yet recruiting, 1 recruiting, 1 unknown. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow this condition Literature Review of Lymphoma, Large B-Cell, Diffuse (DLBCL) trials Research Report on Lymphoma, Large B-Cell, Diffuse (DLBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies MTM-H-001 Injection - Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular | Not applicable | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2026-03-01 | 2026-03-17 |
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies UB-VV111, rapamycin - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) | Phase 1 | Recruiting | Umoja Biopharma | 106 | 2025-03-10 | 2026-10-15 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) Zilovertamab Vedotin, Cyclophosphamide, Doxorubicin - Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2022-07-14 | 2024-10-15 |
| NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy NM-IL-12 - Lymphoma, Large B-Cell, Diffuse (DLBCL) | Phase 2 | Unknown | Neumedicines Inc. | 12 | 2016-11-01 | 2016-08-03 |
Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2)
Cyclophosphamide (1) · Doxorubicin (1) · Interleukin-12 Subunit p35 (1) · Prednisolone (1) · Prednisone (1) · Rituximab (1) · Sirolimus (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Merck Sharp & Dohme LLC (1) · Neumedicines Inc. (1) · Umoja Biopharma (1)
Australia (1) · Canada (1) · China (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Turkey (Türkiye) (1) · United States (1)
Luke Walker, MD (1) · Ning Li, Ph.D (1) · Yossef Kalish, MD (1)